These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31781912)

  • 21. Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221).
    Lafay-Cousin L; Bouffet E; Strother D; Rudneva V; Hawkins C; Eberhart C; Horbinski C; Heier L; Souweidane M; Williams-Hughes C; Onar-Thomas A; Billups CA; Fouladi M; Northcott P; Robinson G; Gajjar A
    J Clin Oncol; 2020 Jan; 38(3):223-231. PubMed ID: 31774708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medulloblastoma with extensive nodularity: a variant occurring in the very young-clinicopathological and immunohistochemical study of four cases.
    Suresh TN; Santosh V; Yasha TC; Anandh B; Mohanty A; Indiradevi B; Sampath S; Shankar SK
    Childs Nerv Syst; 2004 Jan; 20(1):55-60. PubMed ID: 14657995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
    Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
    Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two machine learning methods identify a metastasis-related prognostic model that predicts overall survival in medulloblastoma patients.
    Chen K; Huang B; Yan S; Xu S; Li K; Zhang K; Wang Q; Zhuang Z; Wei L; Zhang Y; Liu M; Lian H; Zhong C
    Aging (Albany NY); 2020 Nov; 12(21):21481-21503. PubMed ID: 33159021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
    Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
    BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
    Kaur K; Kakkar A; Kumar A; Purkait S; Mallick S; Suri V; Sharma MC; Julka PK; Gupta D; Suri A; Sarkar C
    J Neurooncol; 2016 Dec; 130(3):423-430. PubMed ID: 27576698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
    Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort.
    Mynarek M; von Hoff K; Pietsch T; Ottensmeier H; Warmuth-Metz M; Bison B; Pfister S; Korshunov A; Sharma T; Jaeger N; Ryzhova M; Zheludkova O; Golanov A; Rushing EJ; Hasselblatt M; Koch A; Schüller U; von Deimling A; Sahm F; Sill M; Riemenschneider MJ; Dohmen H; Monoranu CM; Sommer C; Staszewski O; Mawrin C; Schittenhelm J; Brück W; Filipski K; Hartmann C; Meinhardt M; Pietschmann K; Haberler C; Slavc I; Gerber NU; Grotzer M; Benesch M; Schlegel PG; Deinlein F; von Bueren AO; Friedrich C; Juhnke BO; Obrecht D; Fleischhack G; Kwiecien R; Faldum A; Kortmann RD; Kool M; Rutkowski S
    J Clin Oncol; 2020 Jun; 38(18):2028-2040. PubMed ID: 32330099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients.
    Priller M; Pöschl J; Abrão L; von Bueren AO; Cho YJ; Rutkowski S; Kretzschmar HA; Schüller U
    Clin Cancer Res; 2011 Nov; 17(21):6791-801. PubMed ID: 21918172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
    Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
    J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
    Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
    Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective family study of childhood medulloblastoma.
    Ng D; Stavrou T; Liu L; Taylor MD; Gold B; Dean M; Kelley MJ; Dubovsky EC; Vezina G; Nicholson HS; Byrne J; Rutka JT; Hogg D; Reaman GH; Goldstein AM
    Am J Med Genet A; 2005 May; 134(4):399-403. PubMed ID: 15759260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.
    Sandén E; Dyberg C; Krona C; Visse E; Carén H; Northcott PA; Kool M; Ståhl N; Persson A; Englund E; Johnsen JI; Siesjö P; Darabi A
    J Neurooncol; 2015 May; 123(1):1-13. PubMed ID: 25820321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.
    Andrade AF; Borges KS; Suazo VK; Geron L; Corrêa CA; Castro-Gamero AM; de Vasconcelos EJ; de Oliveira RS; Neder L; Yunes JA; Dos Santos Aguiar S; Scrideli CA; Tone LG
    Invest New Drugs; 2017 Feb; 35(1):26-36. PubMed ID: 27785591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
    D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histological variants of medulloblastoma are the most powerful clinical prognostic indicators.
    Massimino M; Antonelli M; Gandola L; Miceli R; Pollo B; Biassoni V; Schiavello E; Buttarelli FR; Spreafico F; Collini P; Giangaspero F
    Pediatr Blood Cancer; 2013 Feb; 60(2):210-6. PubMed ID: 22693015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK Expression Is a Novel Marker for the WNT-activated Type of Pediatric Medulloblastoma and an Indicator of Good Prognosis for Patients.
    Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Tarasińska M; Perek-Polnik M; Krętowski A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Matyja E
    Am J Surg Pathol; 2017 Jun; 41(6):781-787. PubMed ID: 28338501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
    Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
    J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.